Flash FinanceUS
Market closed S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · NeoGenomics Laboratories (NEO)

NeoGenomics Q3 revenue rises 12% to $188 million; net loss widens 53% to $27 million

Mixed Impact 3 of 5 earnings Written later

NeoGenomics reported third-quarter 2025 revenue up 12% year over year to $188 million, driven by 18% growth in clinical revenue. The net loss widened 53% to $27 million, and adjusted EBITDA fell 9% to $12.2 million, so revenue growth did not carry through to profit. The company re-affirmed its full-year 2025 guidance for revenue, net loss and adjusted EBITDA, which had been revised on July 29, 2025.

Key points

  • Q3 2025 consolidated revenue of $188 million, up 12%; clinical revenue up 18%, or 15% excluding the Pathline acquisition
  • Net loss of $27 million, up 53% from $18 million in Q3 2024; diluted loss of $0.21 per share
  • Q3 impairment charges of $7.1 million related to the planned sale of Trapelo; adjusted EBITDA of $12.2 million, down 9%
  • Full-year 2025 guidance re-affirmed: consolidated revenue $720 million to $726 million; net loss $116 million to $108 million; adjusted EBITDA $41 million to $44 million

The filing

CompanyNeoGenomics Laboratories (NEO)
Form8-K, current report
Filed with the SECOct 28, 2025, 7:09 AM ET
Accession number0001077183-25-000172

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 6:56 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 28, 2025.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.